

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for detection of an antibody against a pathogenic organism in a liquid sample, wherein said pathogenic organism is selected from the group consisting of bacteria, viruses virus and protozoa protozoan, the method comprising

a) incubating

(1) said liquid sample,

(2) a solid phase,

(3) a first antigen for said antibody, wherein the first antigen ~~comprises at least one marker group, and~~ comprises multiple epitope regions, said epitope regions being identical in amino acid sequence and

(4) a second antigen for said antibody, wherein the second antigen binds to the solid phase,

under conditions to obtain a complex comprising a solid phase-bound second antigen to which is bound the antibody and to which is bound the first antigen; and

b) detecting said antibody by direct or indirect detection of the complex on said solid phase, wherein said antibody is directed against said pathogenic organism; and wherein said first antigen is of formula (Ia) or (Ib)

$(P\text{-})_n T(-L)_n$, (Ia)

$T(-P-L_m)_n$ (lb)

wherein

T is a carrier,

P is a peptide comprising an epitope region wherein said epitope region is reactive with the antibody,

L is the marker group in said first antigen,

- is a covalent coupling,

n is 2-40 and

m is 1-10.

2. (Canceled)

3. (Original) The method of claim 1, wherein the second antigen comprises multiple epitope regions, said epitope regions being identical in amino acid sequence.

4. (Canceled)

5. (Canceled)

6. (Currently amended) The method of claim 1, wherein said indirect detection of said antibody comprises:

c) providing in step b) the first antigen ~~having the marker group comprising~~
wherein L comprises a hapten and a binding partner for the hapten being labeled with a
signal generating group; and

d) detecting the antibody by detecting the signal-generating group.

7. (Original) The method of claim 6, wherein the hapten is selected from the
group consisting of a sterol, a bile acid, a sexual hormone, a corticoid, a cardenolide, a
cardenolide-glycoside, a bufadienol, a steroid-sapogenine and a steroid alkaloid, and
wherein the specific binding partner comprises an antibody for the hapten.

8. (Original) The method of claim 1, wherein the second antigen is biotinylated
and the solid phase is coated with streptavidin or avidin.

9. (Currently amended) The method of claim 1, ~~wherein the at least one of the~~
~~first antigen and~~ or ~~the second antigen comprises a carrier to which the epitope regions~~
~~are covalently coupled,~~ wherein the carrier is non-reactive with the antibody.

10. (Original) The method of claim 9, wherein the carrier is a natural or synthetic
peptide or polypeptide or a synthetic polysaccharide.

11. (Original) The method of claim 10, wherein the carrier is selected from the
group consisting of an albumin, an immunoglobulin, an immunoglobulin fragment, a β -
galactosidase, a polylysine and a dextran.

12. (Original) The method of claim 1, wherein P is a synthetic peptide sequence of 6 to 50 amino acids.

13. (Currently amended) The method for of claim 12, wherein the synthetic peptide sequence is a multimeric antigen comprising multiple, identical epitope regions and further comprises an immunologically inactive spacer region between epitope regions or between the epitope regions and the carrier, said epitope regions being identical in amino acid sequence.

14. (Currently amended) The method of claim 1, wherein P is a recombinant polypeptide sequence comprising a length of up to 1000 amino acids, wherein the polypeptide sequence P comprises a single epitope region or a multiple of an identical epitope region-regions.

15. (Currently amended) The method of claim 1, wherein the first antigen and the second antigen is a recombinant fusion polypeptide wherein P is a mosaic peptide comprising multiple, multiple of immunologically reactive epitope regions optionally linked by immunologically inactive spacer regions.

16. (Withdrawn) A reagent for detection of an antibody against a pathogenic organism in a liquid sample, wherein said pathogenic organism is selected from the group consisting of bacteria, viruses and protozoa, the reagent comprising

- 1) a solid phase;
- 2) a first antigen for the antibody, wherein the first antigen comprises at least one marker group; and
- 3) a second antigen for the antibody, wherein the second antigen binds to the solid phase,

wherein at least one of said antigen is of formula (Ia) or (Ib)



wherein

T is a carrier,

P is a peptide comprising an epitope region, wherein said epitope region is reactive with the antibody,

L is the marker group in said first antigen or a group which binds to the solid phase in said second antigen,

- is a covalent coupling,

wherein n is 2-40 and

wherein m is 1-10.

17. (Withdrawn) The reagent of claim 16, wherein the at least one marker group comprises a hapten and the reagent further comprises a specific binding partner for the hapten, wherein the specific binding partner has a signal-generating group.

18. (Withdrawn) The reagent of claim 16, wherein the second antigen comprises multiple, identical epitope regions and is biotinylated, and wherein the solid phase is coated with streptavidin or avidin.

19. (Currently amended) The method of claim 1, wherein P comprises at least one branching site of the formula

$$P^1\{P^2[P^3(P^4)_t]^s\}_r$$

wherein

P^1 through P^4 are each an amino acid sequence having a length of up to 50 amino acids wherein at least two of P^1 through P^4 comprise a copy of the single epitope and r is 1 or 2,

s is an integer from 0 to 4 and

t is an integer from 0 to 8,

with the proviso that r , s and t are selected to result in P containing the at least one branching site and the several copies of the single epitope.

20. (Original) The method according to claim 19, wherein the at least one branching site is formed by a trifunctional amino acid.


21. (Currently amended) The method of claim [[1]] 19, wherein the several copies of the single epitope are directly covalently coupled to each other or further comprise spacer regions which are covalently coupled between the copies are such

that the several copies are indirectly bound to each other via spacer regions which are covalently coupled between the copies.

22. (Original) The method according to claim 20, wherein the at least one branching site is formed by lysine, ornithine or both.

Claims 23-24 (Canceled).

25. (Previously presented) The method according to claim 1, wherein said second antigen is of formula (Ia) or (Ib)



wherein

T is a carrier,

P is a peptide comprising an epitope region wherein said epitope region is reactive with the antibody,

L is the marker group which binds to the solid phase in said second antigen,

- is a covalent coupling,

n is 2-40 and

m is 1-10.

26. (New) The method according to claim 15, further comprising immunologically inactive spacer regions between said peptides (P).